INV451

About invIOs

invIOs is a Vienna-based biotech developing novel immuno-oncology therapies, with a pipeline featuring both an autologous cell therapy platform (EPiC) and a small molecule program. Its lead asset, APN401, is in Phase 1 trials for solid tumors, while other programs target glioblastoma, AML, and enhanced CAR therapies. The company is privately held, raised a €8.2M Series A, and is led by a team with deep expertise in oncology drug development and Austrian biotech.

Therapeutic Areas